Background: Cardiology consults in cancer centers are often generated by atrial arrhythmias (AA). It is not well established which chemotherapy is associated with the highest AA rate.
Results:
In 1998-2005 there were 1221 HSCTs, 62 (5.1%) of which were complicated by AA. Only melphalan demonstrated significantly higher rate of AA than any other chemotherapy. Out of 438 patients who received melphalan, 48 (11%) developed atrial fibrillation (AF) (35) or supraventricular tachycardia (13) during same hospital admission, and 390 did not (Table) . Patients with AA were older (62.8 ±7.9 versus 55.5 ±10.2, p<0.001). Concomitant hypertension was associated with higher rate of AA. Length of stay was greater (24.9 ±8.9 days versus 19.6 ±5.8 days, p<0.0001) in those who developed AA, even after adjustment for co-morbidities.
Conclusion:
Atrial arrhythmias, mostly AF, complicate about 5% of chemotherapeutic treatments used with HSCT. Melphalan is most arrhythmogenic and is associated with atrial arrhythmias in 11% of patients. Atrial arrhythmias are more common in patients with increased age and concomitant hypertension and result in about a four day increase in length of hospital stay. 
